The March issue heralds many new horizons and asks many new questions for the year ahead. An important national study from the UK provides us bad news on the poor efficacy of vaccines in transplant patients. Elsewhere excellent reviews on diabetes management after liver transplantation, robotic surgery, T cell exhaustion and innate immunity are accompanied by some well written and thought provoking articles on many aspects of liver, kidney, lung and heart transplantation. Guidelines on ERAS will be of use to many programs and a number of papers examine aspects of pediatric transplantation.
Recognized as the world's highest dedicated award for the most outstanding contributions in the field of transplantation.
THE INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS FOR THE 29TH INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY (TTS 2022) – BUENOS AIRES, ARGENTINA, SEPTEMBER 10-14, 2022.
The Transplantation Society celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards to recognize the efforts of scientists who have advanced our understanding of transplantation science and fostered the development of the young investigators who will be the future leaders in our field.
The application will open in January 2022. Deadline for submission is April 10, 2022.Click here for more details
Thanks to generous and dedicated support from the Bambino Gesu Children’s Hospital in Italy, the St. John’s Medical College and Hospital in India has now graduated from the program after completing a fulfilling six-year journey.
St. John’s Medical College and Hospital is now considered to be a center of knowledge, able to support local institutions to advance kidney transplantation in South Asia.
TTS and ISN warmly congratulate these centers on all they have accomplished.Supporting and emerging health centers benefit from such partnerships:
This study investigated the duration and effectiveness of immunity in a prospective cohort of asymptomatic 35,768 health care workers in the United Kingdom who underwent routine polymerase-chain-reaction (PCR) testing. 97% of the participants had received two doses of vaccination and 27% had a previous SARS-CoV-2 infection. A total of 2747 primary infections and 210 reinfections were observed. Two doses of BNT162b2 vaccine were associated with high short-term protection against SARS-CoV-2 infection; this protection waned considerably after 6 months. Infection-acquired immunity waned after 1 year in unvaccinated participants but remained consistently higher than 90% in those who were subsequently vaccinated, even in persons infected more than 18 months previously.
Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0·79, 95% CI 0·69–0·91; p=0·0009). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0·002).
This study evaluated 49 nonresponder kidney transplant recipients with a serologic assessment following a fourth mRNA vaccine. The mean age was 63 years, and 47% were men. None of them had a history of COVID-19 infection nor anti-nucleocapsid IgG. Maintenance therapy consisted of calcineurin inhibitors in 77%, antiproliferative drugs in 83%, and steroids in 57%. A total of 21 of 49 patients (42.8%) seroconverted (i.e., positive serology considered by laboratory thresholds) following the fourth injection, with a mean BAU titer of 82/ml. Of note, 4 of them had a high BAU titer (>264/ml), which can be considered as neutralizing. SARS-CoV-2 infection occurred in 1 patient, who previously developed a low humoral response following 4 injections (BAU, 14.2/ml), presenting with mild symptoms and not requiring oxygen supportive care.